Cellectar to restate previously issued financial statements – company announces receipt of expected delinquency notification letter from nasdaq

Florham park, n.j., aug. 23, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company had received an expected delinquency notification letter (the “notice”) from the listing qualifications staff of the nasdaq stock market llc (“nasdaq”) on august 20, 2024. the notice indicated that the company is not in compliance with the periodic financial report filing requirement set forth in nasdaq listing rule 5250(c)(1) as a result of the company's delay in filing its quarterly report on form 10-q for the quarter ended june 30, 2024 (the “second quarter 10-q”), by the applicable due date.
CLRB Ratings Summary
CLRB Quant Ranking